T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-09-09 12:48 (649 d 00:41 ago) – Posting: # 23282
Views: 2,673

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.

Complete thread:

UA Flag
 Admin contact
23,058 posts in 4,840 threads, 1,641 registered users;
138 visitors (1 registered, 137 guests [including 12 identified bots]).
Forum time: 13:30 CEST (Europe/Vienna)

Even though it’s applied science we’re
dealin’ with, it still is – science!    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz